A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants

NCT04476303 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: BEY2153

Sponsor

BeyondBio Inc.